Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHSE:600645's PB Ratio is ranked better than 59.49% of 1227
companies
in the Biotechnology industry
Industry Median: 2.82
vs SHSE:600645: 2.25
During the past 12 months, Zhongyuan Union Cell & Gene Engineering's average Book Value Per Share Growth Rate was 2.70% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 1.40% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 1.60% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 6.20% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Zhongyuan Union Cell & Gene Engineering was 107.40% per year. The lowest was -37.80% per year. And the median was 6.10% per year.
Back to Basics: PB Ratio
Zhongyuan Union Cell & Gene Engineering (SHSE:600645) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Zhongyuan Union Cell & Gene Engineering PB Ratio Related Terms
Zhongyuan Union Cell & Gene Engineering PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhongyuan Union Cell & Gene Engineering PB Ratio Chart
Zhongyuan Union Cell & Gene Engineering Annual Data
SHSE:600645 vs VRTX, REGN, ALNY: PB Ratio Comparison
For the Biotechnology subindustry, Zhongyuan Union Cell & Gene Engineering's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhongyuan Union Cell & Gene Engineering PB Ratio vs Biotechnology Industry
Zhongyuan Union Cell & Gene Engineering PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Zhongyuan Union Cell & Gene Engineering (SHSE:600645) has a PB Ratio of 2.25 as of Jul. 17, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Zhongyuan Union Cell & Gene Engineering and its competitors. This is 21% below median its historical median of 2.85. Over the past decade, Zhongyuan Union Cell & Gene Engineering's PB Ratio has ranged from 1.86 to 8.99. According to the industry distribution chart, Zhongyuan Union Cell & Gene Engineering ranks #497 out of 1227 companies in the Biotechnology industry, placing it in the top 40.5%.
Is Zhongyuan Union Cell & Gene Engineering's PB Ratio too high?
Zhongyuan Union Cell & Gene Engineering's current PB Ratio of 2.25 is 21% below median its 10-year median of 2.85. Over the past 10 years, this metric has ranged from a low of 1.86 to a high of 8.99. The Biotechnology industry median PB Ratio is 2.82. Zhongyuan Union Cell & Gene Engineering's value of 2.25 is 20.2% below this industry median. Based on the distribution chart, Zhongyuan Union Cell & Gene Engineering ranks #497 out of 1227 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Zhongyuan Union Cell & Gene Engineering has a GF Score™ of 60/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zhongyuan Union Cell & Gene Engineering's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Zhongyuan Union Cell & Gene Engineering ranks #497 out of 1227 companies for PB Ratio. This puts Zhongyuan Union Cell & Gene Engineering in the upper half of its industry. The industry median PB Ratio is 2.82. Zhongyuan Union Cell & Gene Engineering's value of 2.25 is 20.2% below this benchmark. Historically, Zhongyuan Union Cell & Gene Engineering's own PB Ratio has ranged from 1.86 to 8.99 over the past decade. While the company's 10-year median is 2.85 vs. the industry median of 2.82, Zhongyuan Union Cell & Gene Engineering has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.82, based on 1,227 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zhongyuan Union Cell & Gene Engineering's current PB Ratio of 2.25 is 20.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Zhongyuan Union Cell & Gene Engineering and its competitors. For the Biotechnology industry, the median PB Ratio is 2.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zhongyuan Union Cell & Gene Engineering's current PB Ratio is 2.25, which is 21% below median its own 10-year median of 2.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhongyuan Union Cell & Gene Engineering stock overvalued right now?
Based on GuruFocus' analysis, Zhongyuan Union Cell & Gene Engineering (SHSE:600645) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥20.38, compared to a current price of ¥17.85 — trading 12.4% below its estimated fair value. The current PB Ratio is 2.25, which is 21% below median its 10-year median of 2.85 and 20.2% below the Biotechnology industry median of 2.82. Zhongyuan Union Cell & Gene Engineering's overall GF Score™ is 60/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Zhongyuan Union Cell & Gene Engineering (SHSE:600645), the current PB Ratio is 2.25 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zhongyuan Union Cell & Gene Engineering (SHSE:600645) Overvalued in 2026?
Based on GuruFocus' analysis, Zhongyuan Union Cell & Gene Engineering stock appears to be undervalued.
The current stock price of ¥17.85 is trading 12.4% below its estimated GF Value™ of ¥20.38.
GuruFocus considers Zhongyuan Union Cell & Gene Engineering to be Modestly Undervalued.
Key valuation signals for SHSE:600645:
PB Ratio: 2.25 (21% below median its 10-year median of 2.85)
GF Value™: ¥20.38 vs. price of ¥17.85 (12.4% below fair value)
Industry Position: 20.2% below the Biotechnology median (#497 of 1227)
No single metric tells the full story. See the SHSE:600645 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zhongyuan Union Cell & Gene Engineering Business Description
Zhongyuan Union Cell & Gene Engineering Corp Ltd is engaged in stem cell technology research, as well as detection and storage sources of stem cells in China. The company insists on the core strategy upon dual-core development of 'cell + gene' with the major businesses covering various cell storage businesses of newborns and adults; the preparation and storage of cord blood hematopoietic stem cells, umbilical cord mesenchymal stem cells, placental pluripotent stem cells, adipose-derived stem cells and immune cells; genetic testing services relating to children's genes.
60GF Score
Get the complete analysis for SHSE:600645
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600645 has been successfully added to your 
